Navigation Links
Targeting tumors: Ion beam accelerators take aim at cancer
Date:2/11/2014

EVENT: Advances in the design and operation of particle accelerators built for basic physics research are leading to the rapid evolution of machines that deliver cancer-killing beams. Hear about the latest developments and challenges in this field from a physicist, a radiobiologist, and a clinical oncologist, and participate in a discussion about cost, access, and ethics at a symposium organized by the U.S. Department of Energy's Brookhaven National Laboratory ("Targeting Tumors: Ion Beam Accelerators Take Aim at Cancer") and at a related press briefing--both to be held at the 2014 meeting of the American Association for the Advancement of Science.

WHEN: Sunday, February 16, 2014, 8:00 a.m. Central Time (symposium) and 11:00 a.m. (press briefing)

WHERE: Symposium: Hyatt Regency Chicago, Grand Ballroom A; Press Briefing: Swissotel, AAAS briefing room, adjacent to the newsroom, second floor.

WEBCAST: For reporters unable to attend the meeting, the press briefing portion will be webcast live and archived in the AAAS meeting newsroom.

DETAILS: As particle accelerator technology has been incorporated into the clinical practice of treating cancer, the trend has been toward less expensive, more versatile particle beam delivery systems, designed for improved efficacy and greater access for cancer patients around the world. Proton and ion beams are particularly attractive in treating cancer because they deposit most of their energy where the beam stops (i.e., in the tumor) rather than in the tissue through which they travel. As a result, particle beams can deliver cell-killing energy with extreme precision, allowing less damage to adjacent healthy tissue than conventional x-ray or electron radiation treatments.

Protons have been in use for some time at several facilities in the U.S. Beams of heavier ions such as carbon offer promise of even greater efficacy, based on the physics and expected radiobiological effects, as well as on preliminary evidence from facilities operating in Europe and Japan. There are currently no carbon therapy cancer treatment facilities operating in the U.S., and while experience from Europe and Asia suggests that the cost of building one would be considerable, the U.S. National Cancer Institute recently announced a funding opportunity to encourage and support plans for a center for particle beam radiation therapy research.

This symposium and press briefing will explore the scientific rationale behind hadron beam therapy (using protons and heavier ions such as carbon) from the perspectives of a physicist who designs state-of-the-art particle accelerators, a radiobiologist exploring how those particle beams affect cells and tumors, and a radiation oncologist in clinical practice. The session will also address the questions of how to test the relative efficacy of hadron therapy versus conventional radiation treatment and ethical issues related to clinical trials, how to leverage scientific expertise to bring advances driven by basic research to the benefit of society at large, and potential ways to increase treatment access for patients through cost-saving accelerator designs.

SPEAKERS

Stephen Peggs, Physicist, Brookhaven National Laboratory, Adjunct Professor, Stony Brook University (Advances in Accelerator Science Deliver Precision Beams for Cancer Therapy)

Kathryn Held, Radiation Biologist, Associate Professor of Radiation Oncology, Harvard Medical School; associate radiation biologist, Massachusetts General Hospital (Charged Particles for Cancer Treatment: The Benefits of Ions over Photons)

Hak Choy, Chair, Department of Radiation Oncology at the University of Texas Southwestern Medical Center (The Clinical Perspective: Does Proton/Ion Beam Therapy Work?)

Discussant: Ken Peach, Professor, Particle Therapy Cancer Research Institute at Oxford Martin School, Oxford University

Moderator: James Deye, Program Director, Division of Cancer Treatment and Diagnosis, Radiation Research Program, National Cancer Institute

This session was organized by Karen McNulty Walsh, Media & Communications Office, Brookhaven National Laboratory with Co-Organizers Stephen Peggs, Physicist, Brookhaven National Laboratory, and Eric Colby, Office of Science, U.S. Department of Energy.

For more details, including links to talk summaries, see: http://aaas.confex.com/aaas/2014/webprogram/Session6784.html


'/>"/>

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory
Source:Eurekalert

Related medicine news :

1. Cedars-Sinai clinical trial studies vaccine targeting cancer stem cells in brain cancers
2. Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer
3. Chesapeake Drug Detox Launches Program Targeting Substance Abuse Problems Among Adolescents, Adults
4. Home Care Assistance of Vancouver Unveils New and Informative Website Targeting Older Adults is Shaking up the Online Health and Wellness Scene
5. New and Informative Website Targeting Older Adults is Shaking up the Online Health and Wellness Scene
6. New idea for targeting the common cancer protein KRAS
7. GUARDaHEART Hosts an Unforgettable Evening in Celebration of World Heart Day “Targeting Heart Disease”
8. Targeting memory T-cells in Type 1 diabetes
9. Targeting aggressive prostate cancer
10. Nanodrug targeting breast cancer cells from the inside adds weapon: Immune system attack
11. Cancer research brief: Targeting pancreatic cancer drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to your ... clip to clip with high quality 4K lens flare footage," said Christina Austin - ... flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel lens ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... 05, 2016 , ... Edward Buckingham MD , and ... of the newest Sciton laser in January 2017. The Halo is the first ... ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically ...
(Date:12/5/2016)... ... , ... For many years, Andrew G. Zubinas has accumulated over ... of the Lithuanian language and its poetry inspired him in writing “ ... explores all aspects of a living, breathing forest where nothing ever stays the same. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted from December 5, ... Central Awards. , Awards include the Information Security Executive® of the Year, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. announced ... the 2016 Annual Meeting of the American Epilepsy Society ... is indicated as an adjunctive therapy for the treatment ... generalized seizures and primary generalized tonic-clonic seizures (PGTC) in ... and older. Please see Important Safety Information for FYCOMPA, ...
(Date:12/5/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... candidates, presents positive Phase 2a correlative data, as well as ... at the ongoing 58th American Society of Hematology (ASH) Annual ... . ... As previously announced, in ...
Breaking Medicine Technology: